How Often Are PCR Tests Needed After Stopping a CML TKI?

Do not stop taking your TKI without a direct, supervised plan from your hematologist. Attempting Treatment-Free Remission (TFR) in Chronic Myeloid Leukemia (CML) requires a rigorous and strict blood-testing schedule. Once you stop taking your tyrosine kinase inhibitor (TKI), you will undergo RT-qPCR (quantitative reverse-transcription polymerase chain reaction) blood tests very frequently—often every month for the first six months ^[1][2][3]. After that, the frequency usually shifts to every two or three months for the rest of the first year, and then every three months indefinitely ^[2]. Stopping your medication does not mean stopping your medical care; you must remain in close contact with your care team.

Who Can Attempt TFR?

TFR is only safe for carefully selected patients who have achieved a sustained, deep molecular response over several years ^[4][5]. Your care team will review your complete disease history and ensure you meet strict clinical guidelines before you are cleared to stop your medication.

The Standard Monitoring Timeline

While your hematologist will provide an exact schedule tailored to you, major consensus guidelines (including those from the NCCN and ELN) generally advise an intensive testing framework once a patient stops their TKI:

• Months 1 to 6: One RT-qPCR blood test every month ^[1][2][3].
• Months 7 to 12: One RT-qPCR blood test every two to three months ^[2].
• Year 2 and Beyond: One RT-qPCR blood test every three months, indefinitely ^[2].

Note: Having a blood test does not always require a full clinic visit with your doctor. Depending on your care plan, you might get your blood drawn locally while your doctor reviews the results by phone or telehealth.

Why Is the Schedule So Strict?

Frequent monitoring is essential because it often detects molecular changes well before you would feel any physical symptoms. The schedule is heaviest in the first six months because most molecular relapses—when the leukemia-associated molecular signal increases past safe levels—happen within the first six to seven months after stopping treatment ^[6][7][8].

However, monitoring can never truly be stopped. Even though it is rare, late molecular relapses can happen more than 24 months after stopping therapy ^[6][7][8]. Continued surveillance indefinitely ensures that any late changes are caught and addressed promptly ^[2].

Understanding Your Results and Restarting Treatment

RT-qPCR tests measure your BCR::ABL1 transcript level, a molecular signal of the leukemia in your blood. It is important to know that small fluctuations at very low levels are common and do not necessarily mean your leukemia has returned or that your TFR attempt has failed.

Your care team is monitoring your blood to ensure you maintain a Major Molecular Response (MMR). MMR is defined as having a BCR::ABL1 level of 0.1% or lower on the International Scale (IS) ^[9][10][11]. If a routine test shows that your levels have risen above 0.1%, this is considered a loss of MMR, which is the standard threshold that triggers the need to resume TKI therapy ^[9][10][11].

Depending on your local clinic’s protocol, a single result above this threshold might trigger an immediate restart of your TKI, or your doctor might order a rapid repeat test to confirm the rise. Never interpret these results or restart medication on your own. If treatment is restarted, most patients successfully regain a deep response, though your doctor will temporarily increase your testing frequency until that response is confirmed.

Best Practices for Your Tests

Because these critical decisions rely on highly sensitive measurements, it is vital to use the same standardized laboratory with rapid reporting for all your tests ^[4][5]. Mixing different labs can make it harder to track small trends accurately.

If you miss a test due to travel, illness, or insurance issues, contact your care team immediately to reschedule. You should never wait for physical symptoms to tell you if the leukemia is returning.

A Note on Symptoms: Some patients experience “TKI withdrawal syndrome” (such as new joint or muscle pain) shortly after stopping their medication. This is a well-known side effect of stopping the drug and does not automatically mean the leukemia has returned. However, always report new, unusual, or severe symptoms to your care team so they can help you manage them safely.